A Phase I, pharmacokinetic trial, in healthy Asian and Caucasian volunteers for investigating the pharmacokinetic profiles of Eurartesim (trademark) (40 mg Dihydroartemisinin/320 mg Piperaquine Phosphate)

This study is testing the safety and how the body handles a malaria treatment called Eurartesim in healthy Asian and Caucasian volunteers. The study is particularly interested in whether the drug behaves differently between men and women, between Asian and Caucasian people, and between people of different body weights. No participants will actually have malaria — the drug is being tested in healthy people to understand how the body processes it. You may be eligible if: - You are between 18 and 50 years old - You are of Caucasian or Asian background (excluding Indian subcontinent or Middle Eastern) - You are generally healthy with no significant medical conditions - Your BMI is between 19 and 27 kg/m² - You weigh at least 36 kg - You are willing to use two forms of contraception for 90 days after taking the drug You may NOT be eligible if: - You have taken prescription medication in the past 14 days - You are pregnant or breastfeeding - You have significant kidney, liver, heart, or other health problems - You have tested positive for Hepatitis B, Hepatitis C, or HIV - You have participated in a clinical trial within the last 30 days - You have donated blood within the last 90 days - You drink more than 4 units of alcohol daily (men) or 2 units daily (women) - You smoke Talk to your doctor about whether this trial might be right for you.